Clinical Trials Directory

Trials / Completed

CompletedNCT04322240

Alpha Lipoic Acid and Diabetes Mellitus: Potential Effects on Peripheral Neuropathy

Alpha Lipoic Acid and Diabetes Mellitus: Potential Effects on Peripheral Neuropathy and Different Metabolic Parameters

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
90 (actual)
Sponsor
Benha University · Academic / Other
Sex
All
Age
16 Years
Healthy volunteers
Not accepted

Summary

Patients with type 2 DM who are following will be enrolled into the study. Two visits were scheduled for data collection, physical examination and laboratory testing of the patients: the first prior to initiation of alpha lipoic acid (ALA) administration (baseline visit) and the second at the end of the third month following initiation of ALA (2nd visit).

Detailed description

This prospective, Interventional study will be conducted at Benha university hospital for 3 months. Patients with type 2 DM who are following at the outpatient internal medicine \& diabetes Clinics in Benha Univeristy Hospital and are eligible to participate, will be enrolled into the study. Inclusion criteria comprise the following(1) patient's agreement to participate; (2) diabetic peripheral neuropathy diagnosis (3) treatment with alpha lipolic acid (ALA), had to be stable for 3 months during the study. Two visits were scheduled for data collection, physical examination and laboratory testing of the patients: the first prior to initiation of ALA administration (baseline visit) and the second at the end of the third month following initiation of ALA (2nd visit). evaluation include: 1. full neurological evaluation including motor, sensory, ankle reflex, Tests for cardiac parasympathetic action 2. nerve conduction study 3. neuromuscular ultrasound 4. HbA1C 5- HDL-C\& LDL-C

Conditions

Interventions

TypeNameDescription
DRUGAlpha lipoic acidParticipants will be prescribed 600 mg/day ALA (thiotacid) orally, for 3 months, and will be advised not to discontinue this medication

Timeline

Start date
2020-04-02
Primary completion
2020-10-23
Completion
2020-12-23
First posted
2020-03-26
Last updated
2020-12-30

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT04322240. Inclusion in this directory is not an endorsement.